Alnylam Pharmaceuticals (ALNY) PT Lowered to $166 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $174.00 -25.13%
Rating Summary:
28 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
28 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
JPMorgan analyst Anupam Rama lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $166.00 (from $170.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Stifel Downgrades Alnylam Pharmaceuticals (ALNY) to Hold
- Establishment Labs Inc. (ESTA) PT Lowered to $93 at BTIG
- Baxter International (BAX) PT Lowered to $25 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
